KYMR Description — Kymera Therapeutics Inc

Kymera Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Co. is developing KT-474, an active and selective, orally bioavailable IRAK4 degrader, for the treatment of IL-1R/TLR-driven immunology-inflammation conditions and diseases. Co. is developing another group of IRAK4 degraders, which Co. calls IRAKIMiDs for the treatment of MYD88-mutated diffuse large B-cell lymphoma. Co. is developing its selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases.

Company Name: 
Kymera Therapeutics Inc
Number of ETFs Holding KYMR: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   KYMR Weight   KYMR Amount 
 XBI   0.77%   $55,777,789         
 VTI   0.00%   $50,469,113         
 VB   0.03%   $44,435,122         
 IWM   0.06%   $39,183,026         
 VBR   0.06%   $27,748,909         
 IWO   0.11%   $13,850,680         
 VXF   0.01%   $11,945,851         
 VHT   0.03%   $5,146,950         
 VTWO   0.06%   $3,842,733         
 LABU   0.41%   $2,751,260         
List of all 22 ETFs holding KYMR »
Quotes delayed 20 minutes

Strong Buy (3.75 out of 4)
65th percentile
(ranked higher than approx. 65% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding KYMR | Kymera Therapeutics Inc | ETF Channel |

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.